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Crystal Structure of Human Proﬁlaggrin S100 Domain
and Identiﬁcation of Target Proteins Annexin II,
Stratiﬁn, and HSP27
Christopher G. Bunick1,2,6, Richard B. Presland3,4,6, Owen T. Lawrence3,5, David J. Pearton3,5,
Leonard M. Milstone1 and Thomas A. Steitz2
The fused-type S100 protein proﬁlaggrin and its proteolytic products including ﬁlaggrin are important in the
formation of a normal epidermal barrier; however, the speciﬁc function of the S100 calcium-binding domain in
proﬁlaggrin biology is poorly understood. To explore its molecular function, we determined a 2.2 Å-resolution
crystal structure of the N-terminal fused-type S100 domain of human proﬁlaggrin with bound calcium ions. The
proﬁlaggrin S100 domain formed a stable dimer, which contained two hydrophobic pockets that provide a
molecular interface for protein interactions. Biochemical and molecular approaches demonstrated that
three proteins, annexin II/p36, stratiﬁn/14-3-3 sigma, and heat shock protein 27, bind to the N-terminal
domain of human proﬁlaggrin; one protein (stratiﬁn) co-localized with proﬁlaggrin in the differentiating granular
cell layer of human skin. Together, these ﬁndings suggest a model where the proﬁlaggrin N-terminus uses
calcium-dependent and calcium-independent protein–protein interactions to regulate its involvement in
keratinocyte terminal differentiation and incorporation into the corniﬁed cell envelope.
Journal of Investigative Dermatology (2015) 135, 1801–1809; doi:10.1038/jid.2015.102; published online 9 April 2015
INTRODUCTION
Proﬁlaggrin is an~ 400 kDa human protein critical for normal
skin barrier development. It is principally expressed in a
differentiation-dependent manner in the stratum granulosum
(Presland et al., 2006). Loss-of-function mutations in the
proﬁlaggrin (FLG) gene associate it with the skin diseases
atopic dermatitis and ichthyosis vulgaris (Palmer et al., 2006;
Sandilands et al., 2006; Smith et al., 2006; Akiyama, 2010).
Furthermore, variation in copy number of ﬁlaggrin monomers
within the proﬁlaggrin gene is associated with a dry skin
phenotype in the general population (Brown et al., 2012).
In all mammals examined, proﬁlaggrin has four distinct
domains: (1) a 92 amino acid N-terminal S100 fused-type
calcium-binding domain (PF-CABD); (2) highly basic B
domain containing nuclear localization signal; (3) variable
number (species dependent) of ﬁlaggrin units; and (4) short
C-terminal domain (Presland et al., 1992, 2006). Proﬁlaggrin
is highly phosphorylated at Ser/Thr residues within ﬁlaggrin
units and packaged into keratohyalin (KH) granules within the
stratum granulosum (Dale et al., 1980; Lonsdale-Eccles et al.,
1980). During terminal differentiation of the epidermis, when
granular cells transition to dead corneocytes, proﬁlaggrin is
dephosphorylated and processed by multiple proteases to
generate the discrete N-terminal peptide containing the
CABD and B domains (PF-NT) and individual ﬁlaggrin units
(Kam et al., 1993; Resing et al., 1995; Presland et al., 2006).
The PF-NT can translocate (nuclear localization signal within
B domain) into the keratinocyte nucleus both in vitro and
in vivo (Ishida-Yamamoto et al., 1998; Pearton et al., 2002). It
is postulated that PF-NT, once in the nucleus, provides
cellular signals directing events of terminal differentiation; it
may act as a negative feedback signal controlling epidermal
proliferation and homeostasis (Aho et al., 2012).
Proﬁlaggrin, along with six other epidermal proteins, has an
S100 domain fused to additional protein sequences, deﬁning
a “fused S100-type” subfamily within the larger S100 family
(Kizawa et al., 2011). An important unsolved question is why
the epidermis expresses several S100 fused-type proteins,
whose genes cluster on chromosome 1q21. Although isolated
S100 proteins have been studied extensively, the functions of
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fused-type S100 proteins in the epidermis are less clear. Thus,
we investigated the structure and binding interactions of the
most abundant and best understood member of the S100
fused-type family, proﬁlaggrin. Although structures for iso-
lated S100 proteins exist, no atomic resolution structures have
been determined for an S100 fused-type calcium-binding
protein, nor for any region of proﬁlaggrin.
We report here advances in the molecular structure and
biochemical function of the N-terminus of human proﬁlag-
grin. First, we determined the 2.2 Å resolution x-ray crystal
structure of the S100 fused-type CABD of proﬁlaggrin.
Second, several biochemical and yeast two-hybrid (Y2H)
studies demonstrated that the N-terminal fragment of proﬁlag-
grin exists both in vitro and in vivo as a homodimer. Third, co-
immunoprecipitation and mass spectrometry approaches
identiﬁed three protein targets for the N-terminus of proﬁlag-
grin. This research addresses a speciﬁc knowledge gap in
human epidermal barrier biology correlating protein structure
with molecular function.
RESULTS
Biochemical and structural basis for proﬁlaggrin dimerization
The inﬂuence of calcium ions on the aggregation state of
PF-CABD (residues 1–92, inclusive of N-terminal Met) was
analyzed using size-exclusion chromatography. In the pre-
sence of 1 mM EDTA, and the absence of calcium ions,
recombinant PF-CABD separated into a single major peak
(Figure 1a, solid line). In contrast, PF-CABD in 5mM calcium
chloride separated into numerous higher-than-expected
molecular weight (MW) aggregates (Figure 1a, dotted line).
SDS-PAGE of the collected size-exclusion fractions demon-
strated that PF-CABD eluted in a narrow range of fractions in
the absence of calcium (Figure 1b) but in a broad range of
higher-than-expected MW fractions in the presence of 5 mM
calcium (Figure 1c). These data suggest that PF-CABD
undergoes calcium-dependent aggregation.
To further characterize these distinct PF-CABD aggregates,
multiple angle light scattering was performed on PF-CABD in
the absence and presence of calcium. PF-CABD in 1mM
EDTA without added calcium demonstrated a monodisperse
peak of 22,590Da (Figure 1d, solid lines); this is double the
expected calculated MW of 11,194 Da for a PF-CABD
monomer. In the presence of 5 mM (Figure 1d, dotted lines)
or 15 mM (data not shown) calcium chloride, PF-CABD
aggregated into multiple peaks corresponding to complexes
ranging from 30,550 Da to 117,300 Da. Thus, in the absence
of calcium, PF-CABD exists as a stable dimer; however, in the
5–15mM calcium environment tested PF-CABD aggregates
in vitro into higher MW species.
The calcium-dependent conformational opening of PF-
CABD to expose hydrophobic residues was demonstrated by
ﬂuorescence spectroscopy (Figure 1e) using the molecular
probe 8-anilinonaphthalene-1-sulfonic acid (ANS), which
ﬂuoresces greater when bound to hydrophobic surface.
Fluorescence results conﬁrm that PF-CABD undergoes
calcium-dependent conformational/structural change and
suggest non-speciﬁc hydrophobic interactions as the mechan-
ism for higher-order (beyond dimer) protein aggregation.
We subsequently determined the 2.2 Å resolution x-ray
crystal structure of PF-CABD bound to calcium (Table 1). The
structure demonstrates that PF-CABD is a dimer (Figure 2a).
Each PF-CABD monomer forms a four-helix domain similar to
other EF-hand calcium-binding proteins and binds two calcium
ions (Supplementary Figures S1 and S2 online). The crystal
asymmetric unit contains two PF-CABD dimers bound together
for four total copies of PF-CABD per asymmetric unit; eight
calcium ions (two per PF-CABD) are bound (Figure 2b,
Supplementary Figure S3 online). Comparison of PF-CABD
inter-helical angles with other select S100 proteins demon-
strates unique helical orientations, particularly for helix I/IV and
helix II/III interfaces (Supplementary Table S1 online); the four
PF-CABD subunits in the asymmetric unit have similar helical
orientations (average root mean square deviation 0.82 Å).
The dimerization interface is formed primarily by α-helices I
and IV from interdigitating monomers. Helices I and IV from
one monomer form a V-shaped groove that is occupied by
helix I from the dimerization partner. Monomer interdigitation
creates two α-helical planes: “helix I” plane (two antiparallel
N-terminal helices of homodimer) and “helix IV” plane (two
antiparallel C-terminal helices of homodimer). This antipar-
allel dual-plane helical architecture structurally positions the
remainder of proﬁlaggrin on opposite sides of the homodimer
in a sterically feasible state (Figure 2c). Residues stabilizing
the interhelical interfaces are mainly hydrophobic or aromatic
(Supplementary Table S1 online).
Stabilizing interactions exist for the N-terminus (Leu3 and
Leu4) and C-terminus (Tyr85; Supplementary Table S1
online). Tyr85 is stabilized by a four aromatic ring cluster;
Tyr85 of one monomer stacks against several phenylalanine
residues derived from the opposing dimer molecule: Phe14,
Phe70, and Phe73 (Supplementary Figure S4 online). The
total combined area of the molecular surface buried between
dimerizing subunits is ~ 3,000 Å2.
Y2H experiments examined the ability of the human
proﬁlaggrin N-terminus (PF-NT) (CABD (residues 1–92) plus
B domain (residues 93–293)) to form homodimers in vivo. PF-
NT homodimerization was observed only when both bait and
prey constructs contained full-length PF-NT (Supplementary
Figures S5 and S6 online); a similar positive interaction was
seen using full PF-NT and a slightly shorter proﬁlaggrin
peptide (259 residues; AB-259). No Y2H interaction was seen
with shorter constructs containing only part of the B domain.
PF-CABD was unable to form homodimers in yeast, under
conditions where S100A2 could form a functional protein
interaction. Western analysis with PF-NT antibodies showed
that all B domain constructs were abundantly expressed in
yeast cells; however, PF-CABD constructs were less well
expressed but detectable on immunoblots (data not shown).
The in vivo Y2H experiments complement the in vitro
biochemical data and together reveal a dimerization capacity
for human PF-NT.
Proﬁlaggrin N-terminal S100 domain contains a unique
hydrophobic pocket
The molecular surface of the PF-CABD dimer demonstrates
two distinct, symmetric hydrophobic pockets arranged ~ 115o
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opposite each other (Figures 2d and e). Each pocket (one per
PF-CABD subunit) is formed by accessible surface area (ASA)
contributions from 24 residues, 14 of which are hydrophobic
and account for 47.4% of the pocket ASA (Supplementary
Table S2 online). In addition, there are ﬁve polar (31.8%
ASA), two basic (14.4% ASA), and three acidic (6.4% ASA)
residues contributing to the molecular surface properties of
the pocket. The two pockets are connected by a small
hydrophobic surface patch (~226 Å2) formed by adjacent Phe
78 residues. Previous investigations on target selectivity in
S100 proteins showed, despite sharing a common EF-hand
structural motif and moderate sequence similarity, that S100
proteins have unique surface properties at their target protein
binding sites, enabling functional diversity (Bhattacharya
et al., 2004). One dimer subunit contained a polyethylene
glycol 400 molecule bound in the hydrophobic pocket
(Supplementary Figure S7 online).
To analyze primary sequence and molecular surface
conservation across all seven members of the S100 fused-
type protein family, a multiple sequence alignment was
generated (Supplementary Figure S8 online) and conserved
and non-conserved residues mapped onto the PF-CABD
structure (Figure 2f). Excluding the N-terminal Met, S100
fused-type proteins conserve 26 residues, deﬁning “con-
served” as at least 6 out of 7 family members contain the same
amino acid at a given position. Of those 26, only 5 are within
the hydrophobic pocket; thus, of 24 residues comprising the
hydrophobic pocket (Supplementary Table S2 online), only
21% are conserved. This illustrates how S100 fused-type
proteins utilize sequence diversity within the hydrophobic
pocket to generate unique binding interfaces for potential
protein targets in the skin.
Identiﬁcation of human proﬁlaggrin N-terminus-associated
proteins
To identify proteins that associate with the 32 kDa human PF-
NT, we performed immunoprecipitation of human foreskin
cell lysates with proﬁlaggrin N-terminal B1 antibody and
fractionated the total precipitate using SDS-PAGE. Western
analysis of immunoprecipitate with proﬁlaggrin B1 antibody
conﬁrmed the presence of this peptide in the mixture. Eight
bands visible by SDS-PAGE after immunoprecipitation with
proﬁlaggrin B1 antibody were selected for trypsin digestion
and mass spectrometry. Three proteins (in addition to
proﬁlaggrin N-terminus itself) were identiﬁed by mass
spectrometry: annexin II (p36 subunit), stratiﬁn (14-3-3
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Figure 1. Calcium-independent dimerization and calcium-dependent self-aggregation of proﬁlaggrin N-terminal S-100 fused-type calcium-binding domain.
(a) Gel ﬁltration (GF) of PF-CABD with 1mM EDTA (solid line) produced a single peak (180–191ml) but with 5 mM CaCl2 (dotted line) produced multiple high
MW aggregates (100–186ml). Void volume (Vo). (b) SDS-PAGE of GF eluted protein (1 mM EDTA) within 169–197ml fractions demonstrated PF-CABD protein;
none was present in 105ml fraction. (c) SDS-PAGE of GF eluted protein (5 mM CaCl2) in 101–169ml fractions demonstrated PF-CABD high MW aggregates
eluting earlier than expected. L= loaded sample. (d) Light scattering of PF-CABD with 1mM EDTA (solid lines) demonstrated a single homogenous peak with MW
(22,590 Da) of a PF-CABD dimer (scattering distribution labeled ‘D’) but with 5mM CaCl2 (dotted lines) demonstrated multiple peaks of higher than expected MW
(scattering distributions labeled 1–3). (e) Increased ANS ﬂuorescence emission for PF-CABD (2 μM) in 2 mM CaCl2 (dotted line) compared with PF-CABD in 2mM
EDTA (solid line) indicated calcium-dependent structural opening of the protein to expose hydrophobic residues. MW, molecular weight; PF-CABD, N-terminal
S100 fused-type calcium-binding domain of human proﬁlaggrin.
CG Bunick et al.
Molecular Function of Proﬁlaggrin N-terminus
www.jidonline.org 1803
sigma), and heat shock protein 27 (HSP27). Each protein was
represented by three or more peptides encompassing 10.6–
21% of the identiﬁed polypeptide (Supplementary Table S3
online). PF-NT was represented by 19 peptides spanning
128/293 residues (43.7%).
Stratiﬁn and annexin II directly interact with human proﬁlaggrin
N-terminus
Y2H studies were conducted to further dissect interactions of
PF-NT with stratiﬁn and annexin II in vivo (Table 2; Figure 3
and Supplementary Figure S9 online). Human stratiﬁn
associated with both PF-NT and prey proteins containing
the CABD plus varying amounts of the B domain (residues
120–293); however, stratiﬁn did not interact with human PF-
CABD alone. Stratiﬁn additionally interacted with mouse PF-
AB (Table 2; Supplementary Figure S9 online). Stratiﬁn also
forms homodimers in vivo (Yaffe et al., 1997), but in yeast this
interaction is relatively weak compared with the association
with human or mouse PF-NT. Association of human pro-
ﬁlaggrin B domain with stratiﬁn in a calcium-independent
manner is consistent with the presence of several potential
14-3-3 binding sites in proﬁlaggrin (Supplementary Table S4
online).
Annexin II/p36 interacts with human and mouse PF-CABD
domain in a calcium-dependent manner, as well as the
corresponding PF-AB regions (Table 2; Figure 3; Supple-
mentary Discussion online). Removal of the N-terminal 14
amino acids from annexin II, which is the domain that binds
S100A10 (Bharadwaj et al., 2013), prevented its interaction
with human PF-NT (Figure 3). These studies demonstrate that
PF-NT and S100A10 bind the same N-terminal domain of
annexin II. Immunoprecipitation experiments using human
epidermal lysates conﬁrmed that annexin II associates with
PF-NT; however, detectable annexin II could only be pulled
down with proﬁlaggrin N-terminal antibody in the presence of
added calcium (Figure 3c).
To investigate the role of calcium coordination on annexin
II binding and homodimerization, six mutations were made to
key calcium coordination residues in PF-NT (two in N-term-
inal pseudo/non-canonical EF-hand (D21A, E31V) and four in
C-terminal canonical EF-hand (D61A, I62T, D63A, E72V)).
Mutant PF-NT showed diminished binding afﬁnity with
annexin II in yeast (Table 2); by contrast, alteration of calcium
binding did not diminish the strength of interaction with
stratiﬁn (Supplementary Figure S9 online). Homodimerization
of mutant human PF-NT protein in yeast was not affected
(data not shown), consistent with our biochemical data
showing stable homodimer formation in the absence of
calcium.
Stratiﬁn and human proﬁlaggrin N-terminus co-localize in the
epidermal granular layer
To determine whether stratiﬁn and proﬁlaggrin N-terminus
co-localize in human epithelial cells, we performed double-
label immunoﬂuorescence microscopy on paraformaldehyde-
ﬁxed human skin (Figures 4a and b). The results conﬁrm that
PF-NT and stratiﬁn are co-expressed in the stratum granulo-
sum of human skin and co-localize in vivo, primarily at the
cell periphery (Figure 4b).
DISCUSSION
Few atomic resolution structures support the biology currently
known about terminal epidermal differentiation or the stratum
corneum. X-ray crystal structures of the major proteins known
to exist in the stratum corneum (e.g., involucrin, keratins 1/10,
loricrin, proﬁlaggrin) to our knowledge have not been
previously reported. This study correlates proﬁlaggrin struc-
ture with its function and establishes an important foundation
for future structural studies in epidermal biology. Moreover, it
shows that at least one member of the fused-type S100 family
Table 1. Data collection and reﬁnement statistics
Crystal PF-CABD
Diffraction Data
Space group P212121
Unit cell dimensions,
a, b, c (Å) 40.49, 85.28, 96.90
α, β, γ (°) 90, 90, 90
Resolution range (outer shell), Å 50–2.20 (2.24–2.20)1
I/σI 12.7 (1.69)
CC(1/2) in outer shell, % 59.2
Completeness, % 92.9 (93.3)
Rmerge 0.13 (0.854)
Rpim 0.067 (0.439)
Rmeas 0.147 (0.966)
No. of crystals used 1
No. of unique reﬂections 16,492
Redundancy (outer shell) 4.2 (4.1)
Wilson B-factor, Å2 26.9
Reﬁnement
Rwork, % 19.8 (25.2)
Rfree, % 24.2 (32.2)
Rfree test set size, % 5.13
No. of non-hydrogen atoms
Protein 2,978
Ligands/ions (2PE, Ca) 64
Waters 120
r.m.s. Deviations
Bond lengths, (Å) 0.003
Angles, (o) 0.719
Chirality 0.027
Planarity 0.004
Dihedral, (o) 16.61
Average B-factor, (overall) Å2 46.0
Protein/Ca/2PE/waters 47.21/36.70/44.85/42.0
Abbreviations: PF-CABD, N-terminal S100 fused-type calcium-binding
domain of human proﬁlaggrin; r.m.s., root mean square.
1Values in parentheses are for highest-resolution shell.
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follows the paradigm of S100 proteins––i.e., calcium binding,
peptide homodimerization, and physical association with
other intracellular proteins. This is important because the
function of fused-type S100 domains in other epidermal
proteins is unknown.
Advances presented here establish several principles for
epidermal barrier biology: (1) proﬁlaggrin’s N-terminus
undergoes calcium-independent homodimerization and
calcium-dependent non-speciﬁc hydrophobic aggregation;
(2) the S100 fused-type CABD contains a unique hydrophobic
target binding site; (3) proﬁlaggrin participates in protein
interactions with stratiﬁn, annexin II, and HSP27; and (4) the
S100 fused-type CABD and B domain both contribute to
target binding selectivity. Furthermore, we propose a model
whereby calcium promotes aggregation of proﬁlaggrin into
KH storage granules, and in which the identiﬁed binding
partners associate with proﬁlaggrin or the cleaved, soluble
N-terminal peptide, regulating both its nuclear role in
keratinocyte terminal differentiation and incorporation into
the functionally important corniﬁed cell envelope (Figure 4c).
Proﬁlaggrin is stored within KH granules in a calcium-rich
environment; molecular driving forces for KH granule
assembly are not fully known. It has been proposed that both
extensive phosphorylation of ﬁlaggrin units and calcium
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Figure 2. Crystal structure of the N-terminal S100 fused-type calcium-binding domain of human proﬁlaggrin. (a) PF-CABD is biologically a dimer (protein 1,
magenta; protein 2, blue with prime symbol). PF-CABD monomer forms a four-helix bundle. (b) The crystal AU contained two PF-CABD dimers (dimer 1,
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a to display the antiparallel helix IV plane connected to a schematic of remaining proﬁlaggrin sequence. (d) Molecular surface of hydrophobic pocket in PF-CABD
dimer illustrating two hydrophobic pockets (orange color gradient based on the degree of hydrophobicity); polar residues=blue; orientation 40o backward
rotation about x axis compared with panel a. (e) Electrostatic surface potential of PF-CABD dimer, demonstrating acidic calcium-binding loops (red) and
uncharged pocket (white). Basic residues= blue. (f) Only ﬁve residues are conserved in the hydrophobic pocket (labeled, magenta) across S100 fused-type protein
family. Non-conserved residues colored blue. Calcium ions= green. AU, asymmetric unit; B, B domain; F, ﬁlaggrin units; H, helix; L, interhelical linker; PF-
CABD, N-terminal S100 fused-type calcium-binding domain of human proﬁlaggrin.
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binding by the N-terminus are required for KH granule
formation (Dale et al., 1994). The PF-CABD structure
offers several mechanisms of how this domain may contribute
to KH granule assembly: (1) homodimerization facilitates
aggregation of proﬁlaggrin as there are 50% less free
molecules; (2) calcium-bound PF-CABD adopts an open
conformation with exposed hydrophobic patches; (3) hydro-
phobic patches, through self-aggregation or target binding,
offer a protein–protein interaction mechanism for assembly.
HSP27, for example, co-localized with proﬁlaggrin to KH
granules, and loss of HSP27 is associated with hyperkerati-
nization and misprocessing of proﬁlaggrin (O'Shaughnessy
et al., 2007).
Similar to most S100 proteins (Isobe et al., 1981; Hermann
et al., 2012), proﬁlaggrin CABD formed homodimers. PF-NT
(PF-CABD+B domain), the physiologically relevant proteoly-
tic product, also formed homodimers. In the Y2H system,
however, PF-CABD alone did not form homodimers (Supple-
mentary Figure S5 online). The likely explanation for this
discrepancy is that the shorter human PF-CABD protein, but
not the longer PF-CABD+B, is prevented from forming
homodimers in yeast by the attached yeast GAL4 transcription
factor domains. Despite one inconsistent experiment, all other
biochemical, structural, and Y2H studies supported dimeriza-
tion of PF-NT mediated by the S100 domain. Additional
studies are needed to determine whether full-length proﬁlag-
grin dimerizes; for PF-CABD, dimerization potentially enables
binding of two similar or different macromolecules simulta-
neously. This may impart stability to the stratum corneum; for
example, some PF-NT is retained in the stratum corneum and
may be cross-linked as part of the corniﬁed envelope
(Presland et al., 1997).
Identiﬁcation of annexin II, stratiﬁn, and HSP27 as target
proteins for PF-NT demonstrates that human proﬁlaggrin may
be an epidermal signaling molecule or involved in protein
trafﬁcking, in addition to its role in cytokeratin reorganization
and tissue moisturization (Figure 4c). We previously found
that PF-NT binds loricrin, a component of the corniﬁed cell
envelope (Yoneda et al., 2012). Similar to loricrin, stratiﬁn
(epithelial-speciﬁc member of the 14-3-3 protein family also
known as 14-3-3 sigma) interacted with PF-NT and not with
the CABD domain alone. 14-3-3 proteins including stratiﬁn
bind phosphorylated proteins, often to R-X-X-pS sequences
(Yaffe et al., 1997). Human and mouse PF-NT contain several
RXXS sequences (ﬁve in human, six in mouse; Supplementary
Table S4 online) located in the B domain, which may function
as stratiﬁn binding sites. Whereas both the S100 and B
domains cooperatively bound stratiﬁn in a calcium-indepen-
dent manner, annexin II bound only to the S100 domain in a
calcium-dependent manner. Y2H experiments showed that
the N-terminal 14 amino acids of annexin II mediated the
interaction with PF-CABD. Analysis of the PF-CABD structure
bound to the N-terminal 11 residues of annexin II using in
silico molecular docking suggests that six annexin II (Thr2,
Val3, Ile6, Leu7, Lys9, Leu10) and seven proﬁlaggrin (Gln42,
Phe40, Met52, Phe56, Met76, Leu80, and Tyr84) residues
mediate the interaction (Supplementary Figure S10 online).
There is a debate whether Y2H experiments can discriminate
between calcium-regulated and calcium-independent inter-
actions (Deloulme et al., 2003); however, proﬁlaggrin is a
fused-type S100 protein distinct from isolated S100 domains,
with evidence that downstream protein domains (e.g., B
domain) inﬂuence target binding afﬁnity, likely through
domain cooperativity. To conﬁrm identiﬁed protein interac-
tions, multiple techniques were utilized besides Y2H.
In summary, we determined the crystal structure of the
N-terminal S100 CABD of human proﬁlaggrin, analyzed its
suspected target-binding site in molecular detail, and
identiﬁed protein binding partners for each domain of the
cleaved N-terminus. This work enhances our understanding
of proﬁlaggrin as a multifunctional epidermal protein; it is a
precursor to stratum corneum structure and function, engages
in a protein interaction network in human epidermis, and may
be active in epidermal protein–protein signaling and protein
trafﬁcking.
Table 2. Summary of yeast two-hybrid data:
interaction of proﬁlaggrin N-terminus with human
annexin II/p36 and stratiﬁn/14-3-3σ
Bait protein (pOBD
construct)
Prey protein (pOAD
construct)
Strength of
interaction1
Annexin II, 1-339 Human AB +++
Annexin II, 1-339 Human AB (S100
mutant)2
±3
Annexin II, 1-339 Human A ++
Annexin II, 1-339 Mouse AB ++
Annexin II, 1-339 Mouse A ++
Annexin II, 1-44 Human AB ++
Annexin II, 1-44 Mouse A ++
Annexin II, 15-339 Human AB −
Annexin II, 15-339 Mouse A −
Stratiﬁn Human AB4 ++
Stratiﬁn Human AB (S100
mutant)2
++
Stratiﬁn Human A −
Stratiﬁn Human B +
Stratiﬁn Mouse AB ++
Stratiﬁn Mouse A +
Stratiﬁn Mouse B +
Stratiﬁn Stratiﬁn ±3
1+++, robust growth on 10mM 3-amino 1,2,4-triazole (3-AT), ++, weaker
growth (and less colonies) on 10mM 3-AT; +, weak growth on 10mM 3-AT.
2This protein contains mutations in key amino acids involved in calcium
binding (see text for details).
3Very weak but detectable growth on histidine-deﬁcient media containing
10mM 3-AT.
4Stratiﬁn exhibited a positive interaction with all human proﬁlaggrin
constructs containing varying lengths of the B domain––i.e., PF-AB 120,
PF-AB 140, PF-AB 160, PF-AB 218, PF-AB 259, and PF-AB 293. Growth
was similar (++) for all bait–prey combinations on histidine-deﬁcient
media containing 10mM 3-AT.
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MATERIALS AND METHODS
Proﬁlaggrin, annexin II (p36), and stratiﬁn constructs
Design and production of constructs are detailed in Supplementary
Materials and Methods and Supplementary Table S5 online.
Antibodies
Primary antibodies were directed against annexin II (Invitrogen,
Carlsbad, CA), stratiﬁn (Upstate Biotechnology, Lake Placid, NY),
p21 (Cell Signaling Technology, Danvers, MA), and the A (PF-CABD)
and B domains of the human proﬁlaggrin N-terminus (Presland et al.,
1997).
Protein production and puriﬁcation
N-terminal calcium binding domain of human proﬁlaggrin (PF-
CABD) was produced and puriﬁed (detailed in Supplementary Table
S6 online).
Multi-angle light scattering
Apo-PF-CABD (5.2mgml−1) in 50mM Tris-HCl buffer (pH 7.8)
containing 0.5M NaCl and 1mM EDTA was applied at 0.5ml per
minute to Superdex 75 gel ﬁltration column in-line with DAWN
HELEOS II light scattering instrument (Wyatt Technology, Santa
Barbara, CA; laser wavelength 658.0 nm). Data collection/analysis
used Astra software (Wyatt Technology) version 5.3.4.20. After
preparation by overnight dialysis against 50mM Tris-HCl buffer (pH
7.8) containing 0.5M NaCl and either 5 mM or 15mM CaCl2, calcium-
bound samples of PF-CABD were analyzed similar to apo state.
Fluorescence spectroscopy
Fluorescence measurements were made using a SLM Aminco
spectroﬂuorometer (SLM Instruments, Urbana, IL) following estab-
lished protocol (Bunick et al., 2004).
Crystallization and X-ray data collection
PF-CABD (4.6 mgml−1) in 50mM Tris-HCl buffer (pH 7.8) containing
0.5M NaCl and 1mM EDTA was crystallized by sitting drop vapor
diffusion using a reservoir solution of 40% polyethylene glycol
4,000, 50 mM Tris-HCl buffer (pH 8.5), and 0.1M CaCl2. Drops were
prepared by mixing 1 μl PF-CABD with 1 μl reservoir solution.
Crystals grew over 24–48 hours at 25 oC. PF-CABD crystals were
soaked 1–3 minutes in cryoprotectant solution containing 10%
polyethylene glycol 400 in mother liquor prior to ﬂash cooling of the
crystal by direct immersion into a crystal puck storage system
maintained under liquid nitrogen. A native data set on a single crystal
maintained at ~ 100 K was collected using the X-29 beamline
(λ= 1.075 Å) at National Synchrotron Light Source in Brookhaven
National Laboratory. PF-CABD crystallized in the orthorhombic
space group P212121 (cell dimensions: a= 40.49 Å, b= 85.28 Å,
c= 96.90 Å, α= β= γ= 90o) with a unit cell solvent content of 34%.
Diffraction data were processed using HKL2000 (HKL Research,
Charlottesville, VA).
Structure determination, reﬁnement, and analysis
PF-CABD structure was determined by molecular replacement with
MOLREP (Vagin and Teplyakov, 2010) using calcium-bound
ANXA2,1–44
Human AB
ANXA2
humAB
ANXA2,15–339
mouA
kDa E
IP
B1 B1/Ca B1/E p21 Pre
36
30
ANXA2,1–44
mouA
ANXA2
mouA
ANXA2,15–339
Human AB
ANXA2,1–44
Human AB
ANXA2
HumAB
ANXA2,15–339
mouA
ANXA2,1–44
mouA
ANXA2
mouA
ANXA2,15–339
Human AB
Immunoprecipitation assay
Figure 3. The proﬁlaggrin S100 domain interacts with the N-terminus of annexin II. Yeast two-hybrid (Y2H) analysis (a and b) demonstrated that the A (S100)
domain of proﬁlaggrin interacts with the N-terminus of annexin II. (a) Bait (green) and prey (pink) plasmid combinations were plated on histidine, leucine, and
tryptophan-deﬁcient media containing 10mM 3-amino-1,2,4-triazole. Both full length ANXA2 and a truncated N-terminal protein (ANXA2, 1–44) interacted with
human and mouse proﬁlaggrin N-terminus, but an ANXA2 protein lacking the ﬁrst 14 amino acids (ANXA2, 15-339) showed no Y2H signal. (b) Control (leucine
and tryptophan-deﬁcient media) plate showing conﬂuent growth of bait/prey combinations. (c) Association of proﬁlaggrin N-terminus and annexin II in vitro is
calcium dependent. Epidermal proteins were immunoprecipitated with either proﬁlaggrin B domain (B1) antibody, a p21/WAF1 antibody, or a pre-immune
rabbit control. Immunoprecipitated proteins were separated on SDS/polyacrylamide gels and immunoblotted with annexin II antibody. The lanes show
immunoprecipitation with the following: B1 antibody, with no additions; B1/Ca, B1 antibody with the addition of 5 mM CaCl2; B1/E, B1 antibody with the
addition of 5mM EDTA; and p21/WAF1 antibody or pre-immune serum, with no additions. E represents a control epidermal extract to show annexin II.
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S100A12 (PDB 1E8A) as the search model. A simulated annealing
composite omit map generated in PHENIX (Adams et al., 2010) was
necessary to overcome the initial model bias. The PF-CABD structure
underwent iterative rounds of model building (Coot (Emsley and
Cowtan, 2004)) and reﬁnement (PHENIX). Final model of asymmetric
unit contained four PF-CABD molecules (two homodimers), 8
calcium ions, 120 water molecules, and two polyethylene glycol
400 molecules. Final Ramachandran statistics: residues in favorable
regions, 95.1%; in allowed regions, 4.0% and ; in outlier regions,
0.9%. Structural analyses were performed with Coot, UCSF Chimera
(Resource for Biocomputing, Visualization, and Informatics, Uni-
versity of California, San Francisco), INTERHLX (K. Yap, University of
Toronto), and PDBePISA (The European Bioinformatics Institute,
European Molecular Biology Laboratory, UK). Electrostatics
calculated using PDB2PQR (Dolinsky et al., 2004) and Adaptive
Poisson-Boltzmann Software (Baker et al., 2001). Figures prepared
using UCSF Chimera or the PyMOL Molecular Graphics System
(Version 1.5.0.4, Schrödinger, New York, NY).
Yeast two-hybrid assays, expression analysis, and proﬁlaggrin
protein interactions
Details for yeast experiments, immunoprecipitation and mass spectro-
metry studies, and immunoﬂuorescence microscopy are in Supple-
mentary Materials and Methods online.
Statement on use of human materials
Normal human neonatal and adult skin samples, utilized for
immunoﬂuorescence microscopy and immunoprecipitation studies,
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Figure 4. Proﬁlaggrin N-terminus and stratiﬁn co-localize in human epidermal granular cells. Double label immunoﬂuorescence was performed on ﬁxed adult
human skin using antibodies directed against the proﬁlaggrin N-terminus (green) and stratiﬁn (red). Panel a shows that stratiﬁn is expressed throughout the
epidermis, whereas proﬁlaggrin is restricted to the granular layer and anuclear stratum corneum. (b) Shown is a vertical section of adult human skin
immunolabeled with stratiﬁn (red) and proﬁlaggrin N-terminus (green) antibodies, with nuclei counterstained with DAPI. Stratiﬁn is localized through the
cytoplasm in spinous cells, but in the upper granular layer it is concentrated at the cell periphery where it co-localizes with proﬁlaggrin N-terminus (orange
labeling, arrows). Proﬁlaggrin is also present in keratohyalin granules in the characteristic granular pattern but shows little or no association with stratiﬁn when
present in the granular (proﬁlaggrin) form. (c) Proposed biological functions of a calcium-dependent and calcium-independent protein interaction network for
proﬁlaggrin in human epidermis (based on the current study and the previous study by Yoneda et al. (2012)). DAPI, 4′,6-diamidino-2-phenylindole.
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were obtained through the Division of Dermatology with approval
from the University of Washington Institutional Review Board.
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